CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 27 enrolled
Drug / intervention
Rituximab +5 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03943901
NCT03943901Phase 2Active
CompareCT.gov

A Phase II Study of Split-Dose R-CHOP in Older Adults With Diffuse Large B-cell Lymphoma

University of Wisconsin, Madison·interventional·Posted May 9, 2019·Updated Jan 29, 2026

In Brief

A Phase 2 clinical trial evaluating Rituximab, Cyclophosphamide, and 4 other interventions for Diffuse Large B Cell Lymphoma and 2 related conditions. Active but no longer recruiting, targeting 27 participants across 1 site.

Detailed Summary

This study is investigating a new administration schedule of Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone (R-CHOP) chemotherapy for participants with Diffuse Large B-Cell Lymphoma (DLBCL), focusing on an underserved elderly population (aged 75 and up; certain participants 70-74 may be eligible) that is often excluded from clinical trials. Participants can expect to be on study for 2.5 years (treatment for 6 months and 2 years of post treatment follow-up).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiffuse Large B Cell Lymphoma, DLBCL, Cancer
CountriesUnited States
CollaboratorsMedical College of Wisconsin

Timeline

Phase 2Active
20202021202220232024202520262027
First PostedMay 9, 2019
Enrollment StartFeb 17, 2021
Primary CompletionJan 13, 2025
Study CompletionFeb 1, 2027
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 7.1 years ago

Interventions

Rituximabdrug

Rituximab is a monoclonal antibody

Cyclophosphamidedrug

Chemotherapy drug, alkylating agent

Doxorubicindrug

Chemotherapy drug, anthracycline antibiotic

Vincristinedrug

Chemotherapy drug, plant alkaloid

Prednisonedrug

Steroid, anti-inflammatory

Pegfilgrastimbiological

Granulocyte stimulating factor, biologic response modifier